

THRIVE (T1 High Resolution Isotropic Volume Examination) 54

가 (Ki - 67, p53, c - erb B2) 가  
(1 2, 3 ),  
Ki - 67 ( $p=0.045$ ,  $p=0.009$ ), Ki - 67 ( $p=0.009$ ,  
 $p=0.045$ ).

가 가  
(1 - 2005 1 2006 7 49 54  
7). 27 - 73 , 47 . 23 , 26  
가 가  
(8 - 12). (13, 14).

1.5T (Avanto, Siemens, Erlangen, Germany)

T2 - (axial T2 - Weighted turbo spin echo, T2 - weighted TSE) (TR/TE=4000/104, =3 mm, (FOV)=320 mm 512×512), - T2 - (sagittal fat suppressed T2 - weighted TSE)

(TR/TE=7110/106, =3 mm, (FOV)=320 mm 384 × 269) - T1 -  
 (TR/TE=4.42/1.52, =1.5 mm, (FOV)=280 mm 512 × 338) 0.2 mmol/kg Gd - DTPA (Magnevist; Schering Berlin, Germany) 2 cc/sec  
 54  
 (subtraction image) , (maximal intensity projection, MIP)

THRIVE (T1 High Resolution Isotropic Volume Examination)

(time - signal intensity curve)

가 (peak signal intensity), (maximum signal intensity)

(Dpeak, Dmax), (Epeak, Emax)  
 (Speak, Smax)  
 (Wpeak, Wmax) (Fig.

1).

$$\begin{aligned} D_{\text{peak}} &= S_{\text{peak}} - S_{\text{initial}} \\ D_{\text{max}} &= S_{\text{max}} - S_{\text{initial}} \\ S_{\text{peak}} &= D_{\text{peak}} / T_{\text{peak}} \\ S_{\text{max}} &= D_{\text{max}} / T_{\text{max}} \\ E_{\text{peak}}(\%) &= D_{\text{peak}} / S_{\text{initial}} \times 100 \\ E_{\text{max}}(\%) &= D_{\text{max}} / S_{\text{initial}} \times 100 \\ W_{\text{peak}}(\%) &= (S_{\text{peak}} - S_{\text{last}}) / S_{\text{peak}} \times 100 \\ W_{\text{max}}(\%) &= (S_{\text{max}} - S_{\text{last}}) / S_{\text{max}} \times 100 \end{aligned}$$




Fig. 1. Time and Signal Intensity Parameters.

(Tmax)  
 (peak signal intensity) 1  
 , 2 , 2 ,  
 1 ,  
 2 , 3  
 가  
 (Wmax)가 - 5% 5% 2 , 5%  
 3 , - 5% 1  
 가  
 54  
 1 가  
 (Elston - Ellis method) (Modified Black 's nuclear grade) 1, 2, 3  
 , Ki - 67, p53, c - erb B2

**Table 1.** Comparison of Histologic Grade, Nuclear Grade, Estrogen Receptor, Progesteron Receptor, Ki-67, p53 and c-erb B2 with Time of Early Maximum Enhancement (Tpeak) on Dynamic MR

	Time of early maximal enhancement (Tpeak)		
	< 1 minute (n=20)	1 - 2 minutes (n=3)	2 minutes (n=31)
Histologic grade			
I	6	1	11
II	6	2	15
III	8	0	5
Nuclear grade			
I	1	1	6
II	13	1	20
III	6	1	5
Estrogen receptor			
Negative	5	0	7
Positive	15	3	24
Progesterone receptor			
Negative	11	0	9
Positive	9	3	22
Ki-67			
Negative	5	0	0
Positive	15	3	31
p53			
Negative	8	2	11
+1	4	1	6
+2	1	0	4
+3	7	0	10
c-erb B2			
Negative	4	1	7
+1	6	1	10
+2	9	1	9
+3	1	0	5


가  
Mann - Whitney U test, Pearson <sup>2</sup> - tests, Spearman  
rank - correlation test  
가  
54  
( ) 1 ,  
. 27  
0.6 - 6 cm, 2.4 cm  
51 , 1 ,  
1  
1  
가 20 , 1 - 2 3 , 2 31  
(Table 1). (Tpeak)  
Ki - 67  
1 18 , 2 23 , 3 13 ,  
1 8 , 2 34 , 3 12 .  
42 , 12 ,  
34 , 20 . Ki - 67 49 ,  
5 . p53 21 , 1 11 , 2 5 , 3  
17 , c - erb B2 12 , 1 17 , 2 19 ,  
3 6 .  
(peak signal intensity)

**Table 2.** Statistical Relationship Between Parameter of Signal-Intensity Curve and Prognostic Factors

	Histologic Grade	Nuclear Grade	Estrogen Receptor	Progesterone Receptor	Ki-67	p53	c-erb B2
Dpeak	0.375 <sup>a</sup>	0.468 <sup>a</sup>	0.110 <sup>a</sup>	0.426 <sup>a</sup>	0.669 <sup>a</sup>	0.965 <sup>a</sup>	0.313 <sup>a</sup>
Tpeak	0.072 <sup>a</sup>	0.091 <sup>a</sup>	0.837 <sup>a</sup>	0.342 <sup>a</sup>	0.009 <sup>a</sup>	0.436 <sup>a</sup>	0.938 <sup>a</sup>
Epeak	0.790 <sup>a</sup>	0.913 <sup>a</sup>	0.984 <sup>a</sup>	0.830 <sup>a</sup>	rho=0.353 0.965 <sup>a</sup>	0.888 <sup>a</sup>	0.521 <sup>a</sup>
Speak	0.045 <sup>b†</sup>	0.107 <sup>a</sup>	0.536 <sup>a</sup>	0.305 <sup>a</sup>	rho= -0.354 0.009 <sup>a</sup>	0.668 <sup>a</sup>	0.594 <sup>a</sup>
Wpeak	0.919 <sup>a</sup>	0.538 <sup>a</sup>	0.396 <sup>a</sup>	0.663 <sup>a</sup>	0.197 <sup>a</sup>	0.470 <sup>a</sup>	0.185 <sup>a</sup>
Dmax	0.536	0.346 <sup>a</sup>	0.231 <sup>a</sup>	0.565 <sup>a</sup>	0.713 <sup>a</sup>	0.582 <sup>a</sup>	0.447 <sup>a</sup>
Tmax	0.183 <sup>a</sup>	0.070 <sup>a</sup>	0.694 <sup>a</sup>	0.977 <sup>a</sup>	0.045 <sup>a</sup>		
Emax	0.922 <sup>a</sup>	0.892 <sup>a</sup>	0.703 <sup>a</sup>	0.721 <sup>a</sup>	rho=0.277 0.825 <sup>a</sup>	0.374 <sup>a</sup>	0.309 <sup>a</sup>
Smax	0.464 <sup>a</sup>	0.250 <sup>a</sup>	0.955 <sup>a</sup>	0.861 <sup>a</sup>	0.081 <sup>a</sup>	0.511 <sup>a</sup>	0.320 <sup>a</sup>
Wmax	0.821 <sup>a</sup>	0.485 <sup>a</sup>	0.743 <sup>a</sup>	0.887 <sup>a</sup>	0.399 <sup>a</sup>	0.846 <sup>a</sup>	0.093 <sup>a</sup>
Early Enhancement	0.272 <sup>c</sup>	0.393 <sup>c</sup>	0.591 <sup>c</sup>	0.356 <sup>c</sup>	0.378 <sup>c</sup>	0.796 <sup>c</sup>	0.830 <sup>c</sup>
Delayed Enhancement	0.425 <sup>c</sup>	0.250 <sup>c</sup>	0.956 <sup>c</sup>	0.932 <sup>c</sup>	0.075 <sup>c</sup>	0.233 <sup>c</sup>	0.164 <sup>c</sup>

Note. Numbers are *p* value. <sup>a</sup> : Spearman rank-correlation test, <sup>b</sup> : Mann-Whitney U test, <sup>c</sup> : Pearson <sup>2</sup>-tests

†: Histologic grade I versus II, III



**Fig. 2.** A 38-year-old woman with invasive ductal carcinoma, which was histologic grade III, nuclear grade III, estrogen receptor negative, progesterone receptor negative, Ki-67 positive, p53 negative and c-erb B2 positive.


**A.** Early subtraction image shows lobulated well circumscribed and heterogeneous enhanced mass.

**B.** Time-signal intensity curve of the lesion was early peak signal intensity and washout.

(Spearman's test,  $r=0.353$ ,  $p=0.009$ ) (Table 2). , Ki-67 (Tmax) (r=0.277,  $p=0.045$ ). (Speak) (r = -0.354,  $p=0.009$ ) (Fig. 2, 3). (Speak) 1 2, 3 (Mann-Whitney U test,  $p=0.045$ ) (Fig. 2, 3). 가 (Table 2). 1 0 , 2 33 , 3 21 , , p53, c-erb B2, Ki-67 (Table 3). 가 가 (1-8). Ki-67 (proliferation) (2, 5). c-erb B2 (herceptin)

**Table 3.** Comparison of Histologic Grade, Nuclear Grade, Estrogen Receptor, Progesterone Receptor, Ki-67, p53 and c-erb B2 with Kinetic Curve Pattern on Dynamic MR

	MR Kinetic curve pattern		
	Type I (n=0)	Type II (n=33)	Type III (n=21)
Histologic grade			
I	0	13	5
II	0	12	11
III	0	8	5
Nuclear grade			
I	0	7	1
II	0	19	15
III	0	7	5
Estrogen receptor			
Negative	0	8	4
Positive	0	25	17
Progesterone receptor			
Negative	0	12	8
Positive	0	21	13
Ki-67			
Negative	0	5	0
Positive	0	28	21
p53			
Negative	0	13	8
+1	0	8	3
+2	0	1	4
+3	0	11	6
c-erb B2			
Negative	0	10	2
+1	0	11	6
+2	0	10	9
+3	0	2	4



**Fig. 3.** A 49-year-old woman with invasive ductal carcinoma, which was histologic grade I, nuclear grade I, estrogen receptor positive, progesterone receptor negative, Ki-67 negative, p53 negative and c-erb B2 positive.

**A.** Early subtraction image shows irregular, speculated and heterogeneous enhanced mass.

**B.** Time-signal intensity curve of the lesion was relative slow peak signal intensity and washout.

	p53	G1	S		가
(tumor suppressor gene)					
(chemotherapy)					
(4).	,	,	,	, p - 53	
		가		가	
가		(1 - 12).			
Ki - 67					.
(Speak)	가	,	Ki - 67	-	
(Tmax)					
(Tpeak)		가		1.5 mm,	54
				가	.
,		가		가	가 -
(permeability)		(perfusion)			,
(15 - 17).				가	
가		Stomper	가 54	가	
(11) Fischer (12)	Mussurakis (8)				-
가	Tuncbilek (9)	1			,
	,	가			
가	Bone (10)			가	-
					.
, Szabo (14)		c - erb B2			
(short peak time)					
	61	48 (78%)			
, Ki - 67		가			
Ki - 67	가				
		가 . (13)			
		가가 60%			
, 60% 80%					
80% (94%)가		87 82			
가	2	가 54 23 (43%)			
Ki - 67					
가		가			
	87 40 (46%)가				
Ki - 67					
54 21 (39%)					

- Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. *Crit Rev Oncol Hematol* 1999;31:209-223
- Yaghan R, Stanton PD, Robertson KW, Going JJ, Murray GD, McArdle CS. Oestrogen receptor status predicts local recurrence following breast conservation surgery for early breast cancer. *Eur J Surg Oncol* 1998;24:424-426
- Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, et al. c-erb-B2 oncoprotein expression in primary and advanced breast cancer. *Br J Cancer* 1991;63:439-443
- Bergh J. Clinical studies of p53 in treatment and benefit of breast cancer patients. *Endocr Relat Cancer* 1999;6:51-59
- Scholz T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol* 2000;182:311-322
- Elaston CW. Grading of invasive carcinoma of the breast. In Page DL, Anderson TJ *Diagnostic histopathology of the breast*. Edinburgh: Churchill Livingstone, 1987;300-311
- Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. *J Clin Oncol* 1999;17:2334-2340
- Mussurakis S, Buckley DL, Horsman A. Dynamic MR imaging of invasive breast cancer: correlation with tumor grade and other histological factors. *Br J Radiol* 1997;70:446-451
- Tuncbilek N, Karakas HM, Okten OO. Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. *Eur J Radiol* 2005;53:199-205
- Bone B, Aspelin P, Bronge L, Veress B. Contrast enhanced MR

11. Stomper PC, Herman S, Klippenstein DL, Winston JS, Edge SB, Arredondo MA et al. Suspect breast lesions: findings at dynamic gadolinium - enhanced MR imaging correlated with mammographic and pathologic features. *Radiology* 1995;197:387-395
12. Fischer U, Kopka L, Brinck U, Korabiowska M, Schauer A, Grabbe E. Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. *Eur J Radiol* 1997;7:1002-1005
13. . . . .  
2005;52:355-361
14. Szabo BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Bone B.

15. Boetes C, Barentsz JO, Mus RD, van der Sluis RF, van Erning LJ, Hendriks JH, et al. MR characterization of suspicious breast lesions with a gadolinium - enhanced TurboFLASH subtraction technique. *Radiology* 1994;193:777-781
16. Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. *Radiology* 1994;190:485-493
17. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? *Radiology* 1999;211:101-110

202